Trial Profile
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SUPPRESS
- 20 Dec 2020 Status changed from active, no longer recruiting to completed.
- 19 Feb 2020 Planned primary completion date changed from 1 May 2019 to 1 Dec 2020.
- 10 Oct 2019 Planned End Date changed from 1 May 2021 to 1 Dec 2020.